Two Sigma Investments LP Sells 221,365 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Two Sigma Investments LP decreased its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 35.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 397,549 shares of the company's stock after selling 221,365 shares during the quarter. Two Sigma Investments LP owned approximately 0.42% of Scholar Rock worth $17,182,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in SRRK. Vanguard Group Inc. lifted its stake in shares of Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after buying an additional 708,817 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Scholar Rock during the fourth quarter valued at about $274,000. Blackstone Inc. purchased a new position in shares of Scholar Rock in the fourth quarter valued at about $910,000. Rhumbline Advisers boosted its stake in shares of Scholar Rock by 13.2% in the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after acquiring an additional 13,247 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Scholar Rock during the fourth quarter worth about $2,625,000. Institutional investors own 91.08% of the company's stock.

Insider Activity

In other news, insider Tracey Sacco sold 5,000 shares of the business's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the sale, the insider now directly owns 71,750 shares in the company, valued at $2,355,552.50. The trade was a 6.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the transaction, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. The trade was a 56.10% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,798 shares of company stock worth $5,482,238. 13.30% of the stock is currently owned by insiders.

Scholar Rock Trading Down 0.8%

Shares of Scholar Rock stock opened at $30.46 on Friday. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $30.85 and a 200-day moving average price of $35.93. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -12.96 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter last year, the firm posted ($0.59) earnings per share. Equities research analysts anticipate that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.